Since formation in 2011, Fluorogenics have conducted pioneering development in the stabilization of test materials used for genetic identification, personalised, medicine infectious disease detection, veterinary pathology and applied R&D. Our Cyxi proprietary technology and products allow many routine molecular diagnostic tests to be shipped at ambient temperature, negating the traditional industry requirement for an expensive and massively inefficient cold supply chain.

Our Cyxi technology has obvious economic and green credentials in reducing reagent shipping costs and the carbon footprint associated with cold-supply logistics (often tiny volumes of reagent require shipping in large polysterene containers packed with several kg of ice/ dry-ice). More importantly, their technology also has direct application in making molecular testing capability accessible to countries of greatest need, where a combination of climate and unreliable logistics are prohibitive to the deployment of such tests.

Fluorogenics are a self-financing, ethically motivated and quality driven small company who aim to achieve ISO13485 accreditation in 2013 for CE-marking of our products for entry into the global regulated human diagnostics market; an industry expected to exceed $63Bn by 2014 and sustaining growth at 6-8% per annum.